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The effect of rHu-G-CSF on neutrophile restoration in 85
patients was studied. The patients were: 29 with acute lym-
phoblastic leucemia (ALL), 6 with acute non-lymphoblastic
leucemia (ANLL), 1 with chronic myelogeneic leucemia
in blast-transformation, 12 with non-Hodgkin lympho-ma
(NHL), 16 with carcinoma, 10 with aplastic anaemia (AA),
10 with post-radiation neutropenia (PRN) and 1 with Kost-
mann’s syndrome. The daily dose of rHu-G-CSF was 5mcg/kg
for all cases with haematologic malignancies, whereas the
patient with Kostmann’s syndrome was treated with higher
dose, up to 20mcg/kg, due to lack of effect at the end
of ﬁrst week. A dose of 10mcg/kg was applied to patients
with aplastic anaemia and post-radiation neutropenia. The
mean back-ground level of leucocytes just before treat-
ment was 0.73 + 0.13× 10/l and that one of neutrophiles
was 0.17 + 0.09× 10/l. Meanwhile the therapy the authors
registered constantly: leucocyte and granulocyte quantity,
some enzymes, body temperature and clinical status of the
patients. The treatment was discontinued when the abso-
lute neutrophile spectre reached over 1.0× 10/l. Shortest
application was reported for the carcinoma cases: 4.3 days
averagely, followed by ALL: 5.8 days, NHL: 6.3 days, ANLL
- 7.4 days, PRN: 10.3 days, AA: 14.5 days. One (with ALL)
of treated 75 patients had a lethal issue meanwhile the
therapy, another one (with ALL too) shew a recidival mani-
festation; 68 of the rest 73 patients demonstrated a total
recovery and 5 - a particular one (increase of ANC with
over 100%). Only 5 patients of the group registered rapidly-
progressive side effects: 2 with muscular-skeletal pain, 2
with headaches and 1 with vomitting. The nosologic cases
were thoroughly analysed which proved that rHu-G-CSF
shortened considerably the time for recovery from leucope-
nia (opportunity for the so called ‘antibiotic umbrella’ in
neutropenic patients), thus allowing effective results from
the treatment of clinically manifested infectious complica-
tions and intensiﬁcation of chemotherapy.
doi:10.1016/j.ijid.2008.05.1051
66.006
Susceptibility of Oral Anaerobic Bacteria to Fluoro-
quinolones of Various Generations and Molecular Charac-
terization of Resistant Strains
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Russia
Background: Resistance among anaerobic bacteria is
increasing and posing a major problem for clinical peri-
odontology, maxillo-facial and cardiovascular surgery. In the
present study, we attempted to determine susceptibility
of clinical strains of anaerobic bacteria to ﬂuoroquinolones
(FQ) and the frequency for FQ-resistant isolates and to study
some mechanisms of resistance.
Methods: We evaluated 408 strains of anaerobic (Acti-
nomyces israelii, Bacteroides forsithus, Fusobacterium
nucleatum, Peptostreptococcus anaerobius, Porphyromonas
gingivalis, Prevotella intermedia, Streptococcus inter-
medius) and microaerophilic bacteria (H. actinomycetem-
comitans, A. naeslundii, S. milleri) from different patients
with oral diseases, which were collected and tested. The
cultivation was carried out in an anaerobic jar with gas mix-
ture (80% N2; 10% CO2; 10% H2). MICs were determined in
vitro for Gemi-, Gati-, Moxi-, Levo-, Spar- and Ciproﬂoxacin
against these bacteria according to NCCLS, using dilution
method. Besides, then we have examined the chromosomal
mutations in the FQ-resistance-determining region of gyrA,
gyrB genes and parC, parE.
Results: Establishment of the variability of anaerobic
bacteria susceptibility to FQ of various generations. High
level of susceptibility to the generations III-IV FQ was
demonstrated for the tested strains. Gemiﬂoxacin was the
most active and potent regarding all strains of anaerobic
bacteria (susceptibility 100%, MIC90 0,012—0,05mg/L). In
comparison: Moxi - 98,5%, MIC90 0,025—0,25mg/L, Gati -
86,1%, MIC90 0,05—0,5mg/L (generation IV), spar - 85%,
MIC90 0,25—0,5mg/L, Levo - 85%, MIC90 0,25—1mg/L (gen-
eration III), and Ciproﬂoxacin - 70%, MIC90 1—2,5mg/L
(generation II). In FQ-resistant isolates we determined
nucleotide sequences of the FQ-resistant regions of gyrA,
gyrB genes and parC, parE. In 18 clinical FQ-resistant isolates
(S.intermedius and P. gingivalis) we have revealed mutations
in the FQ-resistance-determining region of gyrA and parC
genes - substitutions of serine 83 and 85 to Leucin. Clinical
FQ-resistant isolates showed a wide variation in MIC, ranging
from 2,5 to 12,5mg/L.
Conclusion: Generation IV FQ were found more effec-
tive. Among the group Gemiﬂoxacin demonstrated excellent
activity regarding all anaerobic bacteria. The most common
mechanism of oral anaerobic bacteria resistance to FQ is the
modiﬁcation of type II (DNA gyrase) and IV topoisomerase.
However, the difference in the level of resistance could not
be explained only on the basis of mutations in gyrB or parE.
doi:10.1016/j.ijid.2008.05.1052
